• Explore /
  • Poster
  • / Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC).

Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC).

Abstract Poster

Authors

null

Syed Arsalan Ahmed Naqvi

Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ

Syed Arsalan Ahmed Naqvi , Kunwer Sufyan Faisal , Ammad Raina , Kaneez Zahra Rubab Khakwani , Zaryab Bin Riaz , Vishal S. Shah , Ewan Kemar Cobran , Parminder Singh , Syed A. Hussain , Alan Haruo Bryce , Irbaz Bin Riaz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4591)

DOI

10.1200/JCO.2024.42.16_suppl.4591

Abstract #

4591

Poster Bd #

286

Abstract Disclosures

Similar Posters

First Author: Petros Grivas

First Author: Akshat Saxena

First Author: Michael Seth Weinfeld

First Author: Chiemeka Ike